BRAF and neoplasm: Our aim is to establish an age and histology-dependent rationale regarding the choice of neurooncological tumor types that should undergo routine BRAF V600E mutation screening, thus allowing the possibility of targeted treatment with kinase inhibitors and to determine the efficiency of the BRAF mutation specific VE-1 antibody to detect the V600E hotspot mutation successfully in archival specimens.